Loading…

Paediatric pneumococcal disease in Central Europe

Streptococcus pneumoniae causes considerable global paediatric morbidity and mortality, despite the availability of safe and effective pneumococcal conjugate vaccines (PCVs). To justify the introduction of PCVs, accurate information on the burden of disease is required. Here, we present an appraisal...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 2011-11, Vol.30 (11), p.1311-1320
Main Authors: Prymula, R., Chlibek, R., Ivaskeviciene, I., Mangarov, A., Mészner, Zs, Perenovska, P., Richter, D., Salman, N., Šimurka, P., Tamm, E., Tešović, G., Urbancikova, I., Usonis, V.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Streptococcus pneumoniae causes considerable global paediatric morbidity and mortality, despite the availability of safe and effective pneumococcal conjugate vaccines (PCVs). To justify the introduction of PCVs, accurate information on the burden of disease is required. Here, we present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. The data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database using the search terms ‘pneumococcal’ or ‘ Streptococcus pneumoniae ’, in combination with ‘otitis media’, ‘pneumonia’, ‘meningitis’ or ‘bacteraemia/sepsis’, and ‘[Central European country name]’. The incidence of pneumococcal disease appears to be lower in Central Europe than previously reported for Europe as a whole, with the highest risk in infants aged 0–2 years. The fatality rates in the under fives from invasive infections are up to 40%. A paucity of comprehensive country-specific data on pneumococcal disease burden arises from the lack of homogenous surveillance programmes. Standardised, active surveillance systems are required for the accurate evaluation of the pneumococcal disease burden in the region. Only then can the need for vaccination be addressed.
ISSN:0934-9723
1435-4373
DOI:10.1007/s10096-011-1241-y